…
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public filings and disclosures for FibroBiologics, Inc. are limited; available material identifies it as a clinical-stage biotechnology company focused on biologic therapies. Long-term growth may depend on clinical trial progress, regulatory milestones, strategic partnerships and commercialization of any approved therapies, which could support appeal to investors seeking exposure to early-stage biotech upside.
Key risks include clinical and regulatory failure, a short operating history with limited public disclosure, the need for additional financing that may dilute shareholders, and low trading liquidity.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -18.65M | -11.16M | -16.48M | -5.12M | -1.58M |
| Net income | -18.65M | -11.16M | -16.48M | -5.12M | -1.58M |
| Selling general administrative | 9.24M | 9.23M | 6.52M | 3.32M | 1.06M |
| Selling and marketing expenses | - | - | 0.69M | - | - |
| Gross profit | -0.83M | -0.57M | -0.44M | - | - |
| Reconciled depreciation | 0.83M | 0.57M | 0.44M | 0.09M | 0.00M |
| Ebit | -18.44M | -11.14M | -16.34M | - | - |
| Ebitda | -17.61M | -10.57M | -15.90M | - | - |
| Depreciation and amortization | 0.83M | 0.57M | 0.44M | - | - |
| Operating income | -16.65M | -13.74M | -8.89M | -4.47M | -1.58M |
| Other operating expenses | 16.65M | 13.74M | 8.89M | - | - |
| Interest expense | 0.20M | 0.02M | 0.15M | 0.65M | 0.00M |
| Interest income | 0.25M | 0.25M | 0.00M | - | - |
| Net interest income | 0.04M | 0.23M | -0.15M | -0.65M | -0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 15.82M | 13.74M | 8.89M | 4.47M | 1.58M |
| Cost of revenue | 0.83M | 0.57M | 0.44M | - | - |
| Total other income expense net | -2.00M | 2.58M | -7.60M | - | - |
| Net income from continuing ops | -18.65M | -11.16M | -16.48M | -5.12M | -1.58M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 9.62M | 16.45M | 11.82M | 4.82M | 0.47M |
| Other current assets | 1.46M | 0.24M | 0.05M | 0.03M | 0.02M |
| Total liab | 3.46M | 13.71M | 10.57M | 8.82M | 1.76M |
| Total stockholder equity | 6.16M | 2.73M | 1.25M | -4.00M | -1.29M |
| Other current liab | 0.11M | 0.46M | 7.38M | 0.54M | - |
| Common stock | 0.00M | - | 0.00M | - | - |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -54.16M | -35.52M | -24.36M | -7.87M | -2.75M |
| Cash | 4.89M | 13.98M | 9.16M | 2.27M | 0.41M |
| Total current liabilities | 1.76M | 12.73M | 9.18M | 7.07M | 1.76M |
| Net debt | -2.48M | -3.43M | -7.42M | 3.19M | 0.89M |
| Short term debt | 0.71M | 9.57M | 0.36M | - | - |
| Short long term debt | - | 9.17M | - | 5.45M | 1.30M |
| Short long term debt total | 2.41M | 10.55M | 1.75M | - | - |
| Other stockholder equity | 60.32M | 38.25M | 25.61M | - | - |
| Total current assets | 6.35M | 14.23M | 9.21M | 2.62M | 0.47M |
| Accounts payable | 0.94M | 2.70M | 1.44M | 0.76M | 0.23M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Non currrent assets other | 0.05M | - | - | - | - |
| Non current assets total | 3.27M | 2.22M | 2.61M | 2.20M | 0.00M |
| Capital lease obligations | 2.41M | 1.39M | 1.75M | 2.07M | 0.00M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -0.18M | -0.49M | 0.00M | - |
| Total cashflows from investing activities | -0.26M | -0.18M | -0.49M | - | - |
| Net borrowings | 0.97M | 9.40M | 0.30M | - | - |
| Total cash from financing activities | 7.57M | 16.91M | 13.79M | 5.92M | 1.82M |
| Net income | -18.65M | -11.16M | -16.48M | -5.12M | -1.58M |
| Change in cash | -9.09M | 4.82M | 6.90M | 1.86M | 0.41M |
| Begin period cash flow | 13.98M | 9.16M | 2.27M | 0.41M | 0.00M |
| End period cash flow | 4.89M | 13.98M | 9.16M | 2.27M | 0.41M |
| Total cash from operating activities | -16.39M | -11.90M | -6.40M | -4.07M | -1.41M |
| Issuance of capital stock | 6.59M | 7.51M | 16.14M | 2.15M | 0.00M |
| Depreciation | 0.83M | 0.57M | 0.44M | 0.09M | 0.00M |
| Other cashflows from financing activities | - | 9.40M | 13.49M | - | - |
| Capital expenditures | 0.26M | 0.18M | 0.49M | 0.00M | 0.00M |
| Change in working capital | -3.31M | 0.56M | 0.49M | 0.31M | 0.17M |
| Stock based compensation | 2.69M | 2.22M | 1.76M | 0.27M | 0.00M |
| Other non cash items | 2.05M | -4.09M | 7.39M | 0.39M | - |
| Free cash flow | -16.66M | -12.09M | -6.90M | -4.07M | -1.41M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| FBLG FibroBiologics, Inc. Common Stock |
-0.02 1.93% |
0.98 | - | - | - | 2.25 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 |
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
455 East Medical Center Boulevard, Houston, TX, United States, 77598
281 671 5150
15
| Name | Title | Year Born |
|---|---|---|
| Mr. Peter O'Heeron | Founder, Chairman & CEO | 1964 |
| Mr. Mark C. Andersen C.F.A., CPA, M.B.A. | Chief Financial Officer | 1972 |
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer | 1970 |
| Mr. Ruben A. Garcia | General Counsel | NA |
| Mr. Peter O'Heeron | Founder, Chairperson & CEO | 1964 |
| Mr. Ruben A. Garcia J.D. | General Counsel | 1978 |
| Mr. Ruben A. Garcia J.D. | General Counsel | 1977 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.